A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections

Drug Safety

Volumn 23, Issue 2, 2000, Pages 131-142

  Leflore, Stephani ^a   Anderson, Peter L ^a   Fletcher, Courtney V ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; PENCICLOVIR; VALACICLOVIR; ZIDOVUDINE;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG CAPSULE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENITAL HERPES; HEADACHE; HERPES LABIALIS; HERPES SIMPLEX; HUMAN; IMMUNE DEFICIENCY; LEUKOPENIA; META ANALYSIS; NAUSEA; NEPHROTOXICITY; PATHOPHYSIOLOGY; PHLEBITIS; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; TABLET;

EID: 0033854454     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200023020-00004     Document Type: Review

References (62)

1. 1. Skoldenberg B. Genital herpes: past, present and future. Antiviral Chem Chemother 1997; 8 (1 Suppl.): 43
2. 2. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26: 541-55
3. 3. Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis. Ann Intern Med 1993; 118 (4): 268-72
4. 4. Snoeck R, Andrei G, Gerard M. et al. Successful treatment of progressive mucocutaneous infection due to acyclovir and foscarnet-resistant herpes simplex virus with (s)-1-(3-hydroxy2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Inf Dis 1994; 18: 570-8
5. 5. Montgomerie JZ, Becroft DM, Croxson MC, et al. Herpes simplex virus infection after renal transplantation. Lancet 1969; II: 867-71
6. 6. Carney O, Ross E, Ikkos G, et al. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes. Genitourin Med 1993; 69: 457-9
7. 7. Barton SE. All patients with recurrent genital herpes should be offered suppressive therapy with acyclovir. J Med Virol 1996; 6: 65-6
8. 8. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997; 337: 509-15
9. 9. Scott LL, Sanchez PJ, Jackson GL, et al. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstetrics & Gynecology 1996; 87 (1): 69-73
10. 10. Smith JR, Cowan FM, Munday P. The management of herpes simplex virus infection in pregnancy. Br J Obstet Gynaecol 1998; 105: 255-60
11. 11. Corey L. Herpes simplex virus infections during the decade since the licensure of acyclovir. J Med Virol 1993; Suppl. 1: 7-12
12. 12. Crooks RJ, Murray A. Valaciclovir-a review of a promising new antiherpes agent. Antiviral Chemistry & Chemotherapy 1994; 5 Suppl. 1: 31-37
13. 13. Sacks SL, Wilson BR. Genital herpes: management issues for the next century. Antiviral Chem Chemother 1997; 8 Suppl. 1: 45-50
14. 14. Wald A, Zeh J, Barnum G, et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996; 124 (1 Pt 1): 8-15
15. 15. McKenna D, Murphy G. Mucocutaneous herpes simplex infections. Irish Med J 1995; 88 (6): 202-03
16. 16. Momin F, Chandrasekar PH. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995; 123: 205-15
17. 17. Schlech WF, Meagher N, Cohen AD, et al. A randomized double-blind placebo controlled trial of oral acyclovir in renal allograft recipients. Can J Infect Dis 1993; 4 (2): 84-8
18. 18. Scoular A, Barton S. Therapy for genital herpes in immunocompromised patients: a national survey. Genitourin Med 1997; 73: 391-3
19. 19. Wald A, Corey L, Cone R, et al. Frequent genital herpes simplex virus shedding in immunocompetent women. J Clin Invest 1997; 99(5): 1092-7
20. 20. Balfour HH. Antiviral Drugs. N Engl J Med 1999; 340 (16): 1255-67
21. 21. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR Morb Mortal Wkly Rep 1998; 47 (RR-1): 18-24
22. 22. Amir J, Harel L, Smetana Z, et al. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. BMJ 1997; 314: 1800-3
23. 23. Spruance SL, Hamill ML, Hoge WS, et al. Acyclovir prevents reactivation of herpes simplex labialis in skiers. JAMA 1988; 260 (11): 1597-9
24. 24. Raborn GW, Martel AY, Grace MGA, et al. Oral acyclovir in prevention of herpes labialis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85: 55-9
25. 25. Shaw M, King M, Best JM, et al. Failure of acyclovir cream in treatment of recurrent herpes labialis. BMJ 1985; 291: 7-9
26. 26. Fiddian AP, Ludmilaivanyi. Topical acyclovir in the management of recurrent herpes labialis. Br J Dermatol 1983; 109: 321-6
27. 27. Mindel A, Adler MW, Sutherland S, et al. Intravenous acyclovir treatment for primary genital herpes. Lancet 1982; I (8274): 697-700
28. 28. Thin RN, Nabarro JM, Parker JD, et al. Topical acyclovir in the treatment of initial genital herpes. Br J Vener Dis 1983; 59: 116-9
29. 29. Corey L, Nahmias AJ, Guinan M, et al. Trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med 1982; 306 (220): 1313-9
30. 30. Mertz GJ, Critchlow CW, Benedetti J. et al. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 1984; 252 (9): 1147-51
31. 31. Bryson YJ, Dillion M, Lovett M, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. N Engl J Med 1983; 308 (16): 916-21
32. 32. Reichman RC, Badger GJ, Guinan ME, et al. Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial. J Inf Dis 1983; 147 (2): 336-40
33. 33. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. JAMA 1984; 251 (16): 2103-07
34. 34. Nilsen AE, Aasen T, Halsos AM, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 1982; II (8298): 571-3
35. 35. Brocklehurst P, Kinghorn G, Carney O, et al. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br J Obstet Gynaecol 1998; 105: 275-80
36. 36. Thin RN, Jeffries DJ, Taylor PK, et al. Recurrent genital herpes suppressed by oral acyclovir: a multicentre double blind trial. J Antimicrob Chemother 1985; 16: 219-26
37. 37. Mertz GJ, Jones CC, Mills J, et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. JAMA 1988; 260 (2): 201-6
38. 38. Goldberg LH, Kaufman R, Kurtz TO, et al. Long-term suppression of recurrent genital herpes with acyclovir. Arch Dermatol 1993; 129: 582-7
39. 39. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984; 310 (24): 1551-6
40. 40. Straus SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir. N Engl J Med 1984; 310 (24): 1545-50
41. 41. Shepp DH, Newton BA, Dandliker PS, et al. Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. Ann of Intern Med 1985; 102: 783-5
42. 42. Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982; 73: Suppl 1A: 229-35
43. 43. Wade JC, Newton B, McLaren C, et al. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation. Ann Intern Med 1982; 96 (3): 265-9
44. 44. Whitley RJ, Levin M, Barton N, et al. Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy. J Inf Dis 1984; 150 (3): 323-9
45. 45. Saral R, Ambinder RF, Burns WH, et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. Ann Intern Med 1983; 99: 773-6
46. 46. Prentice HG, Hann IM. Prophylatic studies against herpes infections in severely immunocompromised patients with acyclovir. J Infect 1983; 6 Suppl. I: 17-21
47. 47. Pettersson E, Hovi T, Ahonen J, et al. Prophylactic oral acyclovir after renal transplantation. Transplantation 1985; 39 (3): 279-81
48. 48. Anderson H, Scarffe JH, Sutton RNP, et al. Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. Br J Cancer 1984; 50: 45-49
49. 49. Saral R, Burns WH, Laskin OL, et al. Acyclovir prophylaxis of herpes-simplex virus infections. N Engl J Med 1981; 305 (2): 63-7
50. 50. Seale L, Jones CJ, Kathpalia S, et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose acyclovir. JAMA 1985; 254 (24): 3435-3438
51. 51. Straus SE, Smith HA, Brickman C, et al. Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients. Ann Intern Med 1982; 96: 270-7
52. 52. Stein DS, Graham NMH, Park LP, et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival: analysis of data in the multicenter AIDS cohort study. Ann Intern Med 1994; 121: 100-8
53. 53. Sawyer MH, Webb DE, Balow JE, et al. Acyclovir-induced renal failure. Am J Med 1988; 84: 1067-71
54. 54. Becker BN, Fall P, Hall C, et al. Rapidly progressive acute renal failure due to acyclovir. Am J Kidney Dis 1993; 22 (4): 611-5
55. 55. Spiegal DM, Lau K. Acute renal failure and coma secondary to acyclovir therapy. JAMA 1986; 255 (14): 1882-3
56. 56. Tomson CR, Goodship THJ, Rodger RSC. Psychiatric side-effects of acyclovir in patients with chronic renal failure. Lancet 1985; II (8451): 385-6
57. 57. Bataille P, Devos P, Noel JL, et al. Psychiatric side-effects with acyclovir [letter]. Lancet 1985; II (8457): 724
58. 58. Grella M, Ofosu JR, Klein BL. Prolonged oral acyclovir administration associated with neutropenia and thrombocytopenia. Am J Emer Med 1998; 16 (4): 396-8
59. 59. Kimberlin D, Powell D, Gruber W, et al. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J 1996; 15: 247-54
60. 60. GlaxoWellcome. Acyclovir pregnancy registry and valacyclovir pregnancy registry interim report. GlaxoWellcome Inc. Worldwide Epidemiology; 1984 Jun 1-1988 Jul 31.
61. 61. Englund JA, Zimmerman ME, Swierkosz EM, et al. Herpes simplex virus resistant to acyclovir. Ann Intern Med 1990; 112: 416-22
62. 62. Field HJ, Thackray AM. Can herpes simplex virus latency be prevented using conventional nucleoside analogue chemotherapy? Antiviral Chem Chemother 1997; 8 Suppl. 1: 59-66